Last reviewed · How we verify
Prolonged Cefepime Infusion
Cefepime is a fourth-generation cephalosporin antibiotic that inhibits bacterial cell wall synthesis.
Cefepime is a fourth-generation cephalosporin antibiotic that inhibits bacterial cell wall synthesis. Used for Pneumonia, Urinary tract infections, Skin and soft tissue infections.
At a glance
| Generic name | Prolonged Cefepime Infusion |
|---|---|
| Also known as | Estended Cefepime Infusion |
| Sponsor | Hospital de Clinicas de Porto Alegre |
| Drug class | Cephalosporin antibiotic |
| Target | Penicillin-binding proteins (PBPs) |
| Modality | Small molecule |
| Therapeutic area | Infectious diseases |
| Phase | Phase 3 |
Mechanism of action
Cefepime works by binding to penicillin-binding proteins (PBPs) located inside the bacterial cell wall, resulting in the disruption of the bacterial cell wall synthesis and ultimately leading to cell lysis and death. This mechanism of action is specific to bacterial cells and does not affect human cells.
Approved indications
- Pneumonia
- Urinary tract infections
- Skin and soft tissue infections
Common side effects
- Nausea
- Vomiting
- Diarrhea
- Headache
- Dizziness
Key clinical trials
- Prolonged or Standard Infusion of Cefepime Hydrochloride in Treating Patients With Febrile Neutropenia (PHASE1)
- Prolonged Infusion Cefepime and Nosocomial Infections (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |